title: Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.
authors.affiliation: Department of Hematology-Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA. ritter@uni-greifswald.de
authors.forename: C A
authors.initials: CA
authors.lastname: Ritter
authors.forename: R
authors.initials: R
authors.lastname: Bianco
authors.forename: T
authors.initials: T
authors.lastname: Dugger
authors.forename: J
authors.initials: J
authors.lastname: Forbes
authors.forename: S
authors.initials: S
authors.lastname: Qu
authors.forename: C
authors.initials: C
authors.lastname: Rinehart
authors.forename: W
authors.initials: W
authors.lastname: King
authors.forename: C L
authors.initials: CL
authors.lastname: Arteaga
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D000069347:Erlotinib Hydrochloride; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000069347:Erlotinib Hydrochloride; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab